Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

May 28, 2010
Antiretroviral Treatment Cuts HIV Transmission Rate by 92 Percent
Heterosexual HIV-positive people who are taking antiretroviral (ARV) therapy were 92 percent less likely to pass on the virus to their HIV-negative sex partners, according to a study published online May 27 in The Lancet.
May 27, 2010
Encouraging New Data on the Experimental Hep C Treatment, Telaprevir
Three quarters of people with hepatitis C virus (HCV) who took a regimen including the experimental drug telaprevir managed to clear the virus with just six month’s of treatment, according to a release from the drug’s developer, Vertex Pharmaceuticals, and reporting by The New York Times. Though the study only included HIV-negative people, it was conducted in people with a difficult-to-treat strain of HCV—genotype 1—and the results offer real promise that the drug could substantially increase cure rates in people infected with both HIV and HCV.
FDA Committee Unanimously Recommends Egrifta for Lipodystrophy
A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies' experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy. Though the FDA is not required to follow the recommendations of its advisory committees, it usually does so.
May 25, 2010
Avandia Improves Lipoatrophy in Patients Not on Zerit or Retrovir
Avandia (rosiglitazone) significantly improved HIV treatment–related limb fat loss (lipoatrophy) in people who stop taking Zerit (stavudine) or Retrovir (zidovudine), according to final results of a study published in the June 1 issue of AIDS. Preliminary findings from the same clinical trial were initially reported at the 16th Conference on Retroviruses and Opportunistic Infections in Montreal in February 2009. 
May 21, 2010
Immune Recovery After Stem Cell Transplant Is Same for Lymphoma Patients With HIV
People with HIV and lymphoma who undergo stem cell transplants appear to have no worse degree of immune impairment and recovery than HIV-negative people with lymphoma, according to a study published in the June 15 issue of the journal Clinical Infectious Diseases.
May 20, 2010
Finding About Anti-Inflammatory Cells Could Lead to New HIV Treatments
A new study suggests that HIV throws off the balance of two types of inflammation-reducing cells, thus allowing the virus to persist in the body and cause ongoing damage to the immune system. This finding—published May 19 in the journal Science Translational Medicine and announced by researchers at the University of California in San Francisco (UCSF)—could lead to a new generation of effective HIV medications that operate in a completely different manner from current antiretroviral (ARV) drugs.
May 19, 2010
Daily Zinc Supplements May Slow CD4 Cell Loss and Reduce Diarrhea
Daily zinc supplementation may help slow disease progression, notably in people living with HIV who are unable to maintain viral loads below undetectable while on an antiretroviral (ARV) drug regimen, and reduce diarrhea, according to a new study published in the June 15 issue of Clinical Infectious Diseases.
May 18, 2010
Elevated Heart and Kidney Disease Risk Despite HIV Treatment?
People with HIV have higher levels of blood markers associated with cardiovascular and kidney disease even when their virus is suppressed by antiretroviral (ARV) treatment, according to a new study published in the June 15 issue of The Journal of Infectious Diseases.
May 14, 2010
Frequent Alcohol Use Might Hasten HIV Disease Progression
HIV-positive people who consume two or more alcoholic drinks every day might experience faster disease progression than lighter drinkers, according to a study published online in the journal AIDS Research and Human Retroviruses.
May 13, 2010
Gene Mutation Might Affect HIV Drug Levels in Body
Researchers at Ohio State University announced that they have discovered a gene mutation that can significantly increase blood levels of roughly half of all drugs on the market—including many HIV drugs. This finding could ultimately lead to individualized dosing of medications and potentially reduce the risk of side effects, depending on whether a person has the mutation.
May 11, 2010
HIV Treatment and Lifestyle Factors Influence Death Rates
Many deaths in people with HIV are now preventable—if people are able to not only control HIV, but also make lifestyle changes—according to a study published online May 6 in the journal AIDS.
May 10, 2010
Avexa Shelves Development of HIV Drug Apricitabine
Avexa Limited has decided to end its development of apricitabine (ATC), a nucleoside reverse transcriptase inhibitor (NRTI), according to a May 10 announcement by the company. The decision was reached after an ATC Phase III study was closed and, according to Avexa, because of unsuccessful efforts to partner with other pharmaceutical companies to continue developing the drug.
May 07, 2010
“Self” Gene Variant May Play Role in Better Immune Response to HIV
A variation in a human gene may explain why a small percentage of people living with HIV progress to AIDS only very slowly, or not at all. According to a report detailing the results of a handful of studies, reported in the May 5 issue of Nature, the HLA-B57 gene variation causes a more complete CD8 cell response to HIV in the earliest stages of infection, ultimately giving the immune system the upper hand for decades to come.
May 06, 2010
Merck to Discount Isentress and Crixivan for ADAPs
Merck will continue a price freeze on two of its HIV drugs—Isentress (raltegravir) and Crixivan (indinavir)—and the company will offer steeper discounts to state AIDS Drug Assistance Programs (ADAPs), according to an agreement reached with The National Alliance of State and Territorial AIDS Directors (NASTAD). The new price agreement is intended to address a crisis in ADAP funding that has already resulted in waiting lists in a number of states for people with HIV.
May 04, 2010
Study Finds a Majority Are Still Showing Up Late for HIV Care
A new study shows that a disproportionate number of people living with HIV—notably women, African Americans and older adults—are presenting for care with low CD4 counts, a troubling concern that hasn’t improved significantly in recent years. The results were published in the June 1 issue of Clinical Infectious Diseases.
May 03, 2010
Boston Water Main Break: People Living With HIV Should Boil Water
Households in the City of Boston and surrounding communities should avoid consuming tap water that has not been boiled first until further notice, according to a warning from the Massachusetts Water Resources Authority (MWRA) and reemphasized by AIDS Action Committee of Massachusetts. Though the warning applies to everyone in the aftermath of a recently discovered water main break, it is especially important for people with immune deficiency, including people living with HIV.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.